Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
IsoRay Medical, Inc

Organization & Developments: IsoRay

Parents

2011: IsoRay gets FDA clearance for brain cancer therapy (2011)
2021: IsoRay Is Branching Out
2022: Isoray Isn't Going Anywhere Anytime Soon_ seekingalpha.com
Isoray, Inc. is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body.
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds.
Medical isotopes to treat cancer and other diseases
Proxcelan(TM) (Cesium-131) seeds used in brachytherapy for the treatment of prostate cancer
Received FDA 510(k) clearance in March 2003 for the treatment of all malignancies (e.g., lung, ocular, melanoma, head and neck,
Results in a substantially faster delivery of therapeutic radiation, lower probability of cancer cell survival and reduction of
The fast-acting, high energy medical isotope has demonstrated strong initial clinical results.
Used in low dose radiation (LDR) permanent brachytherapy for prostate cancer.